Corcept Therapeutics: Integrated Drug Discovery Collaboration

Corcept Therapeutics, located in Menlo Park, CA, is a leader in the discovery and development of drugs that regulate the effects of cortisol. Corcept’s scientific expertise surrounding the regulation of cortisol has led to the discovery of an extensive library of novel compounds that may ultimately address life-threatening diseases, such as Cushing’s syndrome, caused by excessive activity of cortisol, and cancer, including prostate and pancreatic cancers.

Deliverables

Sygnature has, so far, delivered two clinical development candidates to Corcept. Both compounds are potent, selective glucocorticoid receptor antagonists designed for oral administration:

Relacorilant (previously known as CORT125134) – Phase II study in patients with Cushing’s syndrome and a Phase I/II clinical trial in combination with Abraxane® in patients with solid tumours, including pancreatic cancer;

CORT125281 – Phase I trial in healthy subjects and a dose-ranging clinical study in combination with Xtandi® (enzalutamide) in patients with castration-resistant prostate cancer.

Sygnature has also developed a novel patented biomarker assay of cortisol activation (WO 2016187347): “Methods are provided for assessing a clinical response to a glucocorticoid receptor antagonist (GRA) in a human subject and for diagnosing Cushing’s syndrome.”

Case Studies

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

If you are human, leave this field blank.

Name
*

Email
*

Message

reCAPTCHA

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.*